Indogulf Cropsciences Limited — Q1 FY26 earnings call

Call held 14 Aug 2025

Management summary

Indogulf Cropsciences Limited reported a strong Q1 FY26, with revenue growing 43.3% YoY to INR 189.4 crores and PAT surging 187.4% to INR 3.9 crores. This growth was primarily driven by domestic B2B and B2C segments, alongside robust performance in biologicals and plant nutrition. Despite a slight gross margin compression due to product mix, management expressed confidence in margin recovery and continued growth, supported by strategic capex, new product launches, and an improving working capital cycle.

Highlights

  • Revenue of INR 189.4 crores, up 43.3% YoY, driven by strong demand in core geographies and disciplined execution.

  • EBITDA grew 66.7% YoY to INR 9.9 crores, supported by operating leverage and cost optimization.

  • PAT increased 187.4% YoY to INR 3.9 crores, reflecting significant profit scaling.

  • Working capital days improved from 225 to 200 days, indicating better operational efficiency.

  • Biologicals segment grew 24.1% YoY, and plant nutrition grew 9.5% YoY, reinforcing focus on sustainable agri-inputs.

Concerns

  • Gross profit margin declined to 22% in Q1 FY26 from 24.6% in Q1 FY25, attributed to a higher proportion of lower-margin B2B sales.

  • Price corrections of 4-5% quarter-over-quarter on average, with some products seeing 8-15% drops.

Key financials

  1. Revenue ₹189.4 Cr +43.3%YoY
  2. Gross Profit ₹41.7 Cr +28.3%YoY
  3. EBITDA ₹9.9 Cr +66.7%YoY
  4. PBT (before exceptional) ₹4.6 Cr +509%YoY
  5. PAT ₹3.9 Cr +187.4%YoY
  6. Gross Margin 22%

What they filed

Q1 FY27: revenue down 12.3%, net profit down 23.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue233 98 123 185 246 +6%109 +10%136 +10%162 −12%
EBITDA27 10 20 9 30 +11%11 +12%21 +2%9 +0%
Net profit17 4 10 3 19 +14%4 +11%12 +25%2 −23%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic B2B
    73.4% Growth
  • Domestic B2C
    17% Growth
  • Crop Protection
    90% Revenue Contribution— Growth
  • Biologicals
    24.1% Growth
  • Plant Nutrition
    9.5% Growth
  • AGPL (AbhiPrakash Globus)
    6% Revenue Contribution— Growth

Capital allocation

high confidence
  • Capex Capex disclosed Partially funded by IPO proceeds, own reserve and surplus, and bank loan (for existing CWIP)
    • Existing infrastructure and fifth manufacturing unit (CWIP) ₹63 Cr
    • New dry flowable plant in Sonipat, Haryana ₹14 Cr
    So out of the proceeds of this IPO, we have paid around INR 35 crores against this investment to our bankers. So now there is no term loan against that capex. This capex is for future capacity expansion, which will be driving the company for another four-digit figure capabilities.
  • Debt Debt disclosed
    • Repayment INR 40 crores loan repaid with IPO money. ₹40 Cr
    • Repayment INR 35 crores from IPO proceeds paid against investment to bankers for existing capex. ₹35 Cr
    So out of the proceeds of this IPO, we have paid around INR 35 crores against this investment to our bankers. So now there is no term loan against that capex.
  • Liquidity Liquidity disclosed Working capital situation improved from 225 days to 200 days.
    The working capital situation is much better. Last year in the first quarter, we were having around 225 days, which has come down to 200 days.

Guidance & targets

Revenue Growth

  • Biologicals and Nutrients Segment Growth Revenue Growth · FY26 · High confidence 30% to 40% increase
    We are expecting around 30% to 40% increase in the total numbers, the total growth of biologicals and nutrients.

    — Sanjay Aggarwal

  • Overall Q2 FY26 Growth Revenue Growth · Q2 FY26 · High confidence more than 20% to 25%
    Second quarter, of course, there will be growth more than 20% to 25%.

    — Sanjay Aggarwal

  • Annual YoY Growth Revenue Growth · annually (FY26, FY27) · High confidence 30% to 35%
    So broadly, we are aspiring for around 30% to 35% year-over-year growth annually.

    — Sanjay Aggarwal

Revenue

  • Q2 FY26 Biologicals and Nutrients Sales Revenue · Q2 FY26 · High confidence around INR 300 crores
    On INR 250 crores sales of last year Q2 FY25, you expect around INR 300 crores odd can be the numbers if we assume 20% to 25% growth?

    — Sanjay Aggarwal

  • Q2 FY26 B2C Topline Revenue · Q2 FY26 · High confidence approximately INR 180 crores to INR 200 crores
    So Q2, broadly B2C will be higher, and we are looking forward for approximately INR 180 crores to INR 200 crores topline figure in Q2.

    — Sanjay Aggarwal

  • Giraffe Mascot New Venture Revenue Revenue · this year (FY26) · High confidence around INR 70 crores to INR 80 crores
    And this year, with the addition of the Giraffe mascot and a new company, we are expecting revenue of around INR 70 crores to INR 80 crores in this new venture.

    — Sanjay Aggarwal

Margin

  • Q2 FY26 Gross Margins Margin · Q2 FY26 · High confidence higher
    And since B2C will be high, the gross margins will definitely be higher in Q2.

    — Sanjay Aggarwal

  • FY26 EBITDA Margins Margin · FY26 · High confidence improving / better

    From 10.9% (FY25) today

    Yes. EBITDA margin will be improving. There will be a growth, definitely.

    — Sanjay Aggarwal

Capacity Expansion

  • Overall Capacity Expansion Capacity Expansion · High confidence almost 50% to 60%
    So, it will be expanding our capacity almost 50% to 60%.

    — Sanjay Aggarwal

Capacity

  • New Dry Flowable Plant Operationalization Capacity · by this fiscal end · High confidence operational
    And by this fiscal end, we are expecting to start this new facility.

    — Sanjay Aggarwal

  • Peak Sales from Expanded Capacity Capacity · Medium confidence INR 1,700 crores to INR 2,000 crores
    Maybe up to INR 1,700 crores to INR 2,000 crores, we can do with these five units.

    — Sanjay Aggarwal

What to watch in Q2 FY26

Q2 FY26 Biologicals and Nutrients Growth

next quarter (Q2 FY26)
Current Q1 FY26 growth of 24.1% YoY
Target 30-40% increase, ~INR 300 crores sales

Why it matters

This high-margin segment is a core focus area and is expected to significantly boost Q2 performance.

We are expecting around 30% to 40% increase in the total numbers, the total growth of biologicals and nutrients. And overall, our Q2 results will demonstrate this performance.

Risks & concerns

  • Climatic changes and regulatory frameworks

    medium

    Climatic changes increase crop stress, necessitating resilient solutions. Tighter regulatory frameworks present both challenges and opportunities for R&D and compliance.

    Management acknowledged

  • Competition from China and weather-related demand fluctuations

    medium

    India faces competition from China and weather-related demand fluctuations in foreign markets as the second largest global agrochemical exporter.

    Management acknowledged

  • Price corrections in the market

    low

    Some products saw 8-15% price corrections, but overall prices remained stable in Q1 with an average 4-5% QoQ correction.

    Management acknowledged

Q&A highlights

7 direct
Volume vs Value Growth in Q1 FY26 Direct
No, the prices are more or less stable. The price corrections are there. And the prices, there has not been any major ups and downs. And broadly, we have focused more on the high value and high cost products. So, broadly, the value-wise growth is there. And the prices remain almost stable in Q1. ... Volume growth is there. But as I mentioned that we worked on high-priced molecules in Q1. So, a slight lower maybe because it's a big basket. So, we cannot quantify exactly the volumes. But broadly, you can say that the growth is there approximately between 35% to 40% since we have worked on high-priced molecules.

Clarified that Q1 growth was primarily value-driven due to focus on high-priced molecules, with overall volume growth estimated at 35-40%.

Asked by Pratik Tholiya

Gross Margin Decline in Q1 FY26 Direct
So, the reason for gross margin coming down was that B2B sale has increased and the B2B sale has very low margins. These margins will be recovered in the second quarter. As our MD has told you, that second quarter is basically worked on the B2C, where the B2B sales slow down and B2C sales increases. So, definitely, the gross margins will be increased in the second quarter.

Addressed the gross margin compression, attributing it to product mix shift towards lower-margin B2B sales in Q1 and projecting recovery in Q2 with higher B2C and biologicals sales.

Asked by Pratik Tholiya

Increase in Staff Costs Direct
So, let me highlight here that we added one more company, which is wholly a subsidiary of Indogulf. The name is AbhiPrakash Globus and the Giraffe is the mascot. So, we did additional hiring in this company. This company is performing well. In this first quarter, it contributed around 6% to the total revenue as well. So, there is an increase in cost because of this new company team recruitment. And we have also added some more professionals, as I mentioned, in our R&D and our marketing area.

Explained the 20% increase in staff costs due to new subsidiary hiring and expansion in R&D/marketing, indicating strategic investments in human capital.

Asked by Pratik Tholiya

Growth Outlook for Plant Nutrient and Biological Business Direct
See, we are aspiring; we are very aggressive in this segment. And of course, this will be the core focus area. We are expecting around 30% to 40% increase in the total numbers, the total growth of biologicals and nutrients. And overall, our Q2 results will demonstrate this performance.

Provided specific growth targets for a key high-margin segment, highlighting its strategic importance and expected contribution to Q2 results.

Asked by Dhavan Shah

Clarity on Capex and CWIP Direct
That is already an infrastructure which we have built up. That is an additional capacity expansion and that is a fifth manufacturing unit. A part of that will be this dry flowable plant also, which will be installed in this fifth facility. So already we have done a capex from our own reserve and surplus. That was pre-IPO and we have taken some bank loan for that. So out of the proceeds of this IPO, we have paid around INR 35 crores against this investment to our bankers.

Clarified the nature and funding of the INR 63 crores CWIP (existing infrastructure, IPO-funded debt repayment) versus the new INR 14 crores capex for the dry flowable plant, detailing capital allocation strategy.

Asked by Raaj

Payback Period for Capex Direct
Maybe in next 4 years, the breakeven will be there. And we will be getting back this money.

Provided a clear financial metric (4-5 year payback at EBITDA level) for the total INR 77 crores capex, indicating management's return expectations.

Asked by Raaj

Capacity Utilization Direct
Yes. So, basically, as you know, this is a cyclical business. So, on an average, it is between 50% to 60% capacity utilization. However, Q2 is the highest utilization because we have a lot of orders and a lot of movement in Q2 in terms of B2C. So, on an average, 50% to 60%, that is the capacity utilization.

Provided insight into current capacity utilization levels and explained the seasonality, with Q2 expected to be the highest due to B2C demand.

Asked by Gursidak Singh

2 min read 5 chapters

Detailed narrative

Robust Q1 FY26 Financial Performance

Indogulf Cropsciences Limited commenced FY26 with a strong financial performance, reporting a 43.3% year-on-year increase in revenue from operations, reaching INR 189.4 crores. This growth was primarily fueled by a 73.4% surge in the domestic B2B segment and a 17.0% rise in the domestic B2C segment. EBITDA saw a significant 66.7% growth to INR 9.9 crores, while Profit After Tax (PAT) scaled 187.4% year-on-year to INR 3.9 crores, demonstrating strong operational leverage and cost optimization.

Margin Dynamics and Product Mix Strategy

Despite the strong top-line growth, gross profit margin for Q1 FY26 stood at 22%, a decrease from 24.6% in Q1 FY25. Management attributed this to a higher proportion of lower-margin B2B sales in the first quarter. However, they anticipate a recovery in Q2, which is typically dominated by higher-margin B2C sales (28-33% gross margin) and high-value biologicals and plant nutrition products (65-95% gross margin). The company's focus on high-priced molecules contributed to value-wise growth in Q1, with overall volume growth estimated at 35-40%.

Strategic Capex and Capacity Expansion

The company is actively pursuing capacity expansion, with INR 63 crores already invested in existing infrastructure and a fifth manufacturing unit, for which INR 35 crores from IPO proceeds were used to repay bank loans. An additional INR 14 crores is being invested in a new dry flowable plant in Sonipat, Haryana, expected to be commissioned by the end of the current fiscal year. This total capex of INR 77 crores is projected to have a payback period of 4-5 years at the EBITDA level and will enable the company to achieve peak sales of INR 1,700-2,000 crores from its five units.

Growth Drivers and Future Outlook

Management provided an optimistic outlook, targeting an annual year-on-year growth of 30-35% for FY26, FY27, and FY28. Q2 FY26 is expected to see over 20-25% growth, with B2C topline projected at INR 180-200 crores and biologicals/nutrients sales around INR 300 crores. The new subsidiary, AbhiPrakash Globus, is expected to contribute INR 70-80 crores in FY26. The company's R&D pipeline includes multiple formulations and new products, with trials successfully completed for products entering the market in the next 12-18 months, supporting future growth and margin improvement.

Operational Efficiency and Market Trends

Operational efficiency improved, with working capital days reducing from 225 to 200 days year-on-year. Staff costs increased by 20% due to new hiring for the subsidiary and R&D/marketing, but as a percentage of sales, it was lower than last year. The global agrochemical market is expected to grow in 2025, driven by increasing global population, climate change pressures, and the need for sustainable food production, with a focus on integrated pest management and advanced technologies like AI and machine learning.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls